Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 35730 | 93 | 29.7 | 62% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 8 | 4 | CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL | 1276458 |
| 131 | 3 | HEMATOLOGY//HAEMOPHILIA//TRANSFUSION | 66936 |
| 966 | 2 | CLOPIDOGREL//PRASUGREL//TICAGRELOR | 10690 |
| 35730 | 1 | TRIFLUSAL//HTB//CAS 322 79 2 | 93 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | TRIFLUSAL | authKW | 6544132 | 37% | 59% | 34 |
| 2 | HTB | authKW | 738764 | 3% | 75% | 3 |
| 3 | CAS 322 79 2 | authKW | 656680 | 2% | 100% | 2 |
| 4 | 2 HYDROXY 4 TRIFLUOROMETHYL BENZOIC ACID | authKW | 328340 | 1% | 100% | 1 |
| 5 | 2 HYDROXY 4 TRIFLUOROMETHYLBENZOIC ACID HTB | authKW | 328340 | 1% | 100% | 1 |
| 6 | ACETYLSALICYLIC ACID PLATELET ACTIVATION PLATELET VESSEL WALL INTERACTION SUBENDOTHELIUM | authKW | 328340 | 1% | 100% | 1 |
| 7 | ANTI INFLAMMATORY POLYMER CONJUGATES | authKW | 328340 | 1% | 100% | 1 |
| 8 | BINARY PROBABILITY MODEL | authKW | 328340 | 1% | 100% | 1 |
| 9 | BRAIN ANOXIA REOXYGENATION | authKW | 328340 | 1% | 100% | 1 |
| 10 | CHOONGWAE PHARMA CORP | address | 328340 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Pharmacology & Pharmacy | 469 | 42% | 0% | 39 |
| 2 | Materials Science, Biomaterials | 133 | 6% | 0% | 6 |
| 3 | Cardiac & Cardiovascular System | 101 | 14% | 0% | 13 |
| 4 | Peripheral Vascular Diseases | 68 | 9% | 0% | 8 |
| 5 | Engineering, Biomedical | 35 | 5% | 0% | 5 |
| 6 | Medicine, General & Internal | 21 | 9% | 0% | 8 |
| 7 | Toxicology | 13 | 4% | 0% | 4 |
| 8 | Hematology | 12 | 4% | 0% | 4 |
| 9 | Clinical Neurology | 12 | 6% | 0% | 6 |
| 10 | Polymer Science | 11 | 5% | 0% | 5 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | CHOONGWAE PHARMA CORP | 328340 | 1% | 100% | 1 |
| 2 | MED AREACLIN DEV UNIT | 328340 | 1% | 100% | 1 |
| 3 | NEPHROL HYPERTEN CARDIOVASC | 328340 | 1% | 100% | 1 |
| 4 | SERV ANAT PATOLUNIDAD INVEST CLIN BIOPATHOL EX | 328340 | 1% | 100% | 1 |
| 5 | BIOANAL PHARMACOKINET UNIT | 164169 | 1% | 50% | 1 |
| 6 | CIHR GRP VASC COGNIT IMPAIRMENT | 164169 | 1% | 50% | 1 |
| 7 | CLIN EXPT MEDMED | 164169 | 1% | 50% | 1 |
| 8 | DRUG DISCOVERY PK | 164169 | 1% | 50% | 1 |
| 9 | PIFRECV | 164169 | 1% | 50% | 1 |
| 10 | CLIN DEV MED ADVICE | 82084 | 1% | 25% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | EUROPEAN HEART JOURNAL SUPPLEMENTS | 5112 | 4% | 0% | 4 |
| 2 | METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 2013 | 4% | 0% | 4 |
| 3 | VITAE-REVISTA DE LA FACULTAD DE QUIMICA FARMACEUTICA | 1832 | 1% | 1% | 1 |
| 4 | REVISTA ECUATORIANA DE NEUROLOGIA | 1389 | 1% | 0% | 1 |
| 5 | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH | 1368 | 2% | 0% | 2 |
| 6 | BMC PHARMACOLOGY & TOXICOLOGY | 1271 | 1% | 0% | 1 |
| 7 | COMPARATIVE HAEMATOLOGY INTERNATIONAL | 972 | 1% | 0% | 1 |
| 8 | REVISTA CLINICA ESPANOLA | 877 | 3% | 0% | 3 |
| 9 | EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS | 852 | 2% | 0% | 2 |
| 10 | CARDIOVASCULAR DRUG REVIEWS | 780 | 1% | 0% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | MURDOCH, D , PLOSKER, GL , (2006) TRIFLUSAL - A REVIEW OF ITS USE IN CEREBRAL INFARCTION AND MYOCARDIAL INFARCTION, AND AS THROMBOPROPHYLAXIS IN ATRIAL FIBRILLATION.DRUGS. VOL. 66. ISSUE 5. P. 671-692 | 27 | 53% | 22 |
| 2 | MCNEELY, W , GOA, KL , (1998) TRIFLUSAL.DRUGS. VOL. 55. ISSUE 6. P. 823-833 | 17 | 81% | 53 |
| 3 | GONZALEZ-CORREA, JA , DE LA CRUZ, JP , (2006) TRIFLUSAL: AN ANTIPLATELET DRUG WITH A NEUROPROTECTIVE EFFECT?.CARDIOVASCULAR DRUG REVIEWS. VOL. 24. ISSUE 1. P. 11-24 | 20 | 51% | 9 |
| 4 | ANNINOS, H , ANDRIKOPOULOS, G , PASTROMAS, S , SAKELLARIOU, D , THEODORAKIS, G , VARDAS, P , (2009) TRIFLUSAL: AN OLD DRUG IN MODERN ANTIPLATELET THERAPY. REVIEW OF ITS ACTION, USE, SAFETY AND EFFECTIVENESS.HELLENIC JOURNAL OF CARDIOLOGY. VOL. 50. ISSUE 3. P. 199 -207 | 21 | 44% | 14 |
| 5 | LEE, HW , LIM, MS , SEONG, SJ , LEE, JM , PARK, J , SEO, JJ , YUN, HY , BAEK, IH , KWON, KI , YOON, YR , (2011) A PHASE I STUDY TO CHARACTERIZE THE MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF NEW ENTERIC-COATED TRIFLUSAL FORMULATIONS IN HEALTHY MALE VOLUNTEERS.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 7. ISSUE 12. P. 1471 -1479 | 12 | 67% | 1 |
| 6 | PARK, SM , LEE, J , SEONG, SJ , PARK, JG , GWON, MR , LIM, MS , LEE, HW , YOON, YR , YANG, DH , KWON, KI , ET AL (2014) POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF TRANSFORMED BINARY EFFECT DATA OF TRIFLUSAL IN HEALTHY KOREAN MALE VOLUNTEERS: A RANDOMIZED, OPEN-LABEL, MULTIPLE DOSE, CROSSOVER STUDY.BMC PHARMACOLOGY & TOXICOLOGY. VOL. 15. ISSUE . P. - | 9 | 64% | 0 |
| 7 | SHIN, S , KIM, KJ , CHO, IJ , HONG, GR , JANG, Y , CHUNG, N , RAH, YM , CHANG, HJ , (2015) EFFECT OF TRIFLUSAL ON PRIMARY VASCULAR DYSREGULATION COMPARED WITH ASPIRIN: A DOUBLE-BLIND, RANDOMIZED, CROSSOVER TRIAL.YONSEI MEDICAL JOURNAL. VOL. 56. ISSUE 5. P. 1227 -1234 | 12 | 46% | 1 |
| 8 | GE, J , DING, LK , YANG, J , JIA, YY , LU, CT , DING, Y , SONG, Y , SONG, W , WEN, AD , (2015) EFFECT OF FOOD ON THE PHARMACOKINETICS OF TRIFLUSAL AND ITS MAJOR ACTIVE METABOLITE, 2-HYDROXY-4-TRIFLUOROMETHYL BENZOIC ACID, IN HEALTHY SUBJECTS.INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS. VOL. 53. ISSUE 3. P. 272 -276 | 6 | 86% | 0 |
| 9 | COSTA, J , FERRO, JM , MATIAS-GUIU, J , ALVAREZ-SABIN, J , TORRES, F , (2005) TRIFLUSAL FOR PREVENTING SERIOUS VASCULAR EVENTS IN PEOPLE AT HIGH RISK.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 3. P. - | 13 | 50% | 2 |
| 10 | DALLA-VOLTA, S , (1999) PHARMACOLOGICAL BASIS OF ANTIPLATELET DRUGS IN ACUTE MYOCARDIAL INFARCTION: FOCUS ON TRIFLUSAL.EUROPEAN HEART JOURNAL SUPPLEMENTS. VOL. 1. ISSUE F. P. F7 -F11 | 13 | 57% | 2 |
Classes with closest relation at Level 1 |